Agility Clinical, the specialist consulting and clinical-research organisation (CRO) set up around two years ago in Carlsbad, US, has formed a partnership with PSR Orphan Experts, a European orphan-drug consulting and clinical-research company based in the Netherlands.
The alliance will give the two companies’ respective clients access to orphan-drug development expertise and services on both sides of the Atlantic, the new partners said.
Both companies specialise in complex clinical-development programmes that call for innovative regulatory and development approaches, they noted.
“With few CROs focused on rare diseases, partnering with another like company to share knowledge and experiences strengthens our services to clients, and our reach,” commented Ellen Morgan, chief executive officer (CEO) of Agility Clinical.
Given the current challenges in orphan-drug development, it is “of crucial importance to provide innovative and solid infrastructure and expert services”, added Roger Legtenberg, CEO of PSR Orphan Experts.
The number of rare diseases with no currently available treatment is estimated at around 6,800, according to the US National Institutes of Health.
